# Genprex, Inc.: overview GNPX · Nasdaq · CIK 1595248 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/gnpx.md) · [Financials](/companies/gnpx/financials.md) · [Filings](/companies/gnpx/filings.md) · [Insiders](/companies/gnpx/insiders.md) Latest reported revenue: [$0](/filings/0001437749-24-010426.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Apr 1, 2024 (XBRL us-gaap:Revenues, accession 0001437749-24-010426). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001437749-23-008847.md) | [0.0](/filings/0001437749-24-010426.md) | [0.0](/filings/0001437749-25-010311.md) | [0.0](/filings/0001437749-25-010311.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.42)](/filings/0001437749-22-007680.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(14.3)](/filings/0001437749-23-008847.md) | [(17.6)](/filings/0001437749-24-010426.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gnpx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Cheviot Value Management, LLC](/funds/1427147.md) | 2026-06-30 | $519 | 1,000 | | New +1,000 | | [HARBOUR INVESTMENTS, INC.](/funds/810121.md) | 2026-06-30 | $56 | 108 | | New +108 | ## Recent filings [All 488 filings](/companies/gnpx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 07:01 ET | [8-K](/filings/0001437749-26-033053.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-033053 | | 2026-08-18 | 07:01 ET | [8-K](/filings/0001437749-26-028250.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-028250 | | 2026-08-14 | 09:27 ET | [10-Q](/filings/0001437749-26-027846.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027846 | | 2026-08-05 | 16:31 ET | [8-K](/filings/0001437749-26-025938.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001437749-26-025938 | | 2026-08-03 | 07:02 ET | [8-K](/filings/0001437749-26-025302.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-025302 | | 2026-07-30 | 16:31 ET | [8-K](/filings/0001437749-26-025074.md) | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-025074 | | 2026-07-14 | 09:23 ET | [8-K](/filings/0001437749-26-023480.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-023480 | | 2026-06-22 | 09:02 ET | [8-K](/filings/0001437749-26-021262.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-021262 | | 2026-06-18 | 16:01 ET | [8-K](/filings/0001437749-26-021134.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-021134 | | 2026-06-12 | 17:05 ET | [8-K](/filings/0001437749-26-020501.md) | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-020501 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010346.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1595248 - Tickers: GNPX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: TX - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 07:02 ET. No prices; not investment advice.